UPDATE: Viridian Therapeutics' REVEAL-1 Study Shows Elegrobart Efficacy; Q4W CAS And Q8W Diplopia Endpoints Miss Statistical Significance; Shares Trading Lower, Future Trial Dependence May Concern Investors

Benzinga Newsdesk www.benzinga.com Negative 97.0%

Neg 97% Neu 0% Pos 0%

Comments

No comments yet. Be the first!